scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, has announced the closing of a senior secured term loan and a royalty investment together totaling up to US$125 million from funds managed by Perceptive Advisors, a leading life-sciences focused investor.

Latham & Watkins LLP represented scPharmaceuticals in the transaction with a team led by partners Haim Zaltzman and Dan Van Fleet, with associates Erin Cusenbary, Tony Noh, and Ian Drazen. Advice was also provided on tax matters by partner Kirt Switzer, with associate Gregory Conyers; on healthcare and life sciences matters by partner Jekkie Kim, with associates Mizuna Sekine and Patrick Chew; on FDA regulatory matters by partner Betty Pang and counsel Chad Jennings; on ERISA matters by partner Josh Friedman; and on corporate matters by partner Wesley Holmes.